www.bioshin.com Open in urlscan Pro
16.162.117.43  Public Scan

Form analysis
1 forms found in the DOM

GET /search-result

<form action="/search-result" method="get" id="mid-solr-search-form" accept-charset="UTF-8">
  <div id="search-div">
    <div class="form-item js-form-item form-type-textfield js-form-type-textfield form-item-q js-form-item-q form-no-label form-group"><input id="solrstrap-searchbox-form" autocomplete="off" onfocus="this.value = this.value;"
        class="form-text form-control" data-drupal-selector="edit-q" type="text" name="q" value="" size="60" maxlength="128" placeholder="Search"></div>
  </div><button data-drupal-selector="submitsearchbutton" class="button js-form-submit form-submit btn-primary btn icon-before" type="submit" id="submitSearchButton" name="op" value="Search"><span class="icon-search"></span></button><input
    autocomplete="off" data-drupal-selector="form-4njxdm8np2rw7jnkypuufd02dbz4bfnovcswoh-tluw" type="hidden" name="form_build_id" value="form-4nJXdm8np2rw7jnKYpUufD02dbZ4bfNOVCswOH_tluw"><input data-drupal-selector="edit-mid-solr-search-form"
    type="hidden" name="form_id" value="mid_solr_search_form">
</form>

Text Content

Home
 * Home
 * About BioShin
 * Science & Pipeline
 * News & Events
 * Contact Us

BackHome
 * 主页

BackAbout BioShin
 * Management and Operations

BackNews & Events
 * Press Releases
 * Events & Presentations

Skip to main content
 * Home
    * 主页

 * About BioShin
    * Management and Operations

 * Science & Pipeline
 * News & Events
    * Press Releases

 * Contact Us



Mobi buttom


WHO WE ARE

Based in Shanghai, BioShin Limited is a biopharmaceutical company focused on the
discovery, development and commercialization of novel, life-improving treatments
for patients with neuro-immune diseases in China and the Asia-Pacific region.
BioShin is the wholly owned subsidiary of Biohaven (NYSE:BHVN). Beyond its
current research and development portfolio, BioShin’s strategic vision also
includes partnering with biopharmaceutical companies, inside and outside China,
that seek to discover, develop, and commercialize assets in the region. By
bringing together promising assets and a diverse management team with
international expertise, BioShin is growing a nimble organization with an
entrepreneurial spirit to serve patients throughout the region.

Learn about Migraine in ChinaLearn about Migraine in China button


HIGHLY EXPERIENCED TEAM WITH INDUSTRY AND ACADEMIC ROOTS

MEET OUR TEAMAbout Highly experienced team with industry and academic roots


LATEST NEWS

02/14/2022Press Releases

Biohaven 和BioShin 宣布在中国和韩国进行的Rimegepant（NURTEC® ODT）偏头痛急性治疗的关 键试验达到主要终点

02/14/2022Press Releases

Biohaven and BioShin Announce Positive Pivotal Trial Results of rimegepant
(NURTEC® ODT) for the Acute Treatment of Migraine in China and Korea

08/06/2021Press Releases

China NMPA Approved the IND Application for New Glutamate Modulator Troriluzole,
Signalling Fresh Hope for OCD Patients

08/06/2021Press Releases
China NMPA Approved the IND Application for New Glutamate Modulator Troriluzole,
Signalling Fresh Hope for OCD Patients
02/14/2022Press Releases
Biohaven 和BioShin 宣布在中国和韩国进行的Rimegepant（NURTEC® ODT）偏头痛急性治疗的关 键试验达到主要终点
02/14/2022Press Releases
Biohaven and BioShin Announce Positive Pivotal Trial Results of rimegepant
(NURTEC® ODT) for the Acute Treatment of Migraine in China and Korea
08/06/2021Press Releases
China NMPA Approved the IND Application for New Glutamate Modulator Troriluzole,
Signalling Fresh Hope for OCD Patients
02/14/2022Press Releases
Biohaven 和BioShin 宣布在中国和韩国进行的Rimegepant（NURTEC® ODT）偏头痛急性治疗的关 键试验达到主要终点
 * 1
 * 2
 * 3

View All NewsView All News button


MAIN NAVIGATION

 * Home
 * About BioShin
 * Science & Pipeline
 * News & Events
 * Contact Us

© 2021 BioShin




SITE SERVICES

 * Privacy Policy
 * Terms & Conditions
 * Sitemap

Back to top